strata skin sciences inc - SSKN

SSKN

Close Chg Chg %
1.27 -0.04 -3.15%

Closed Market

1.23

-0.04 (3.15%)

Volume: 35.19K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Company Overview: strata skin sciences inc - SSKN

SSKN Key Data

Open

$1.24

Day Range

1.20 - 1.25

52 Week Range

1.19 - 3.86

Market Cap

$7.48M

Shares Outstanding

5.89M

Public Float

3.93M

Beta

0.26

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.62

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

71.51K

 

SSKN Performance

1 Week
 
3.36%
 
1 Month
 
-18.00%
 
3 Months
 
-48.10%
 
1 Year
 
-58.59%
 
5 Years
 
-91.63%
 

SSKN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About strata skin sciences inc - SSKN

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

SSKN At a Glance

STRATA Skin Sciences, Inc.
5 Walnut Grove Drive
Horsham, Pennsylvania 19044
Phone 1-215-619-3200 Revenue 33.56M
Industry Medical Specialties Net Income -10,086,000.00
Sector Health Technology 2024 Sales Growth 0.612%
Fiscal Year-end 12 / 2025 Employees 106
View SEC Filings

SSKN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.33
Price to Book Ratio 2.441
Price to Cash Flow Ratio 58.93
Enterprise Value to EBITDA -217.505
Enterprise Value to Sales 0.564
Total Debt to Enterprise Value 0.869

SSKN Efficiency

Revenue/Employee 316,622.642
Income Per Employee -95,150.943
Receivables Turnover 6.389
Total Asset Turnover 0.85

SSKN Liquidity

Current Ratio 1.135
Quick Ratio 0.981
Cash Ratio 0.588

SSKN Profitability

Gross Margin 56.853
Operating Margin -16.072
Pretax Margin -30.558
Net Margin -30.052
Return on Assets -25.547
Return on Equity -114.224
Return on Total Capital -47.107
Return on Invested Capital -41.124

SSKN Capital Structure

Total Debt to Total Equity 330.632
Total Debt to Total Capital 76.778
Total Debt to Total Assets 44.497
Long-Term Debt to Equity 324.035
Long-Term Debt to Total Capital 75.246
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Strata Skin Sciences Inc - SSKN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
29.98M 36.16M 33.36M 33.56M
Sales Growth
+29.83% +20.63% -7.75% +0.61%
Cost of Goods Sold (COGS) incl D&A
10.13M 14.39M 14.90M 14.48M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.09M 5.69M 5.90M 5.31M
Depreciation
2.49M 2.79M 3.20M 3.31M
Amortization of Intangibles
1.60M 2.90M 2.70M 2.00M
COGS Growth
+13.08% +42.13% +3.50% -2.79%
Gross Income
19.85M 21.77M 18.46M 19.08M
Gross Income Growth
+40.44% +9.66% -15.19% +3.36%
Gross Profit Margin
+66.22% +60.20% +55.34% +56.85%
2021 2022 2023 2024 5-year trend
SG&A Expense
24.25M 26.42M 24.78M 24.48M
Research & Development
1.43M 1.03M 1.32M 883.00K
Other SG&A
22.82M 25.39M 23.46M 23.59M
SGA Growth
+33.18% +8.93% -6.19% -1.23%
Other Operating Expense
- - - -
-
Unusual Expense
- (2.03M) 3.19M 3.86M
EBIT after Unusual Expense
(2.37M) (4.65M) (9.51M) (9.26M)
Non Operating Income/Expense
15.00K 89.00K 231.00K 1.11M
Non-Operating Interest Income
15.00K 89.00K 231.00K 242.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
314.00K 926.00K 1.64M 2.11M
Interest Expense Growth
+414.75% +194.90% +77.11% +28.48%
Gross Interest Expense
314.00K 926.00K 1.64M 2.11M
Interest Capitalized
- - - -
-
Pretax Income
(2.67M) (5.49M) (10.92M) (10.26M)
Pretax Income Growth
+35.41% -105.31% -99.09% +6.10%
Pretax Margin
-8.91% -15.17% -32.74% -30.56%
Income Tax
34.00K 63.00K (92.00K) (170.00K)
Income Tax - Current - Domestic
22.00K 23.00K 28.00K 16.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
12.00K 40.00K (120.00K) (186.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(2.71M) (5.55M) (10.83M) (10.09M)
Minority Interest Expense
- - - -
-
Net Income
(2.71M) (5.55M) (10.83M) (10.09M)
Net Income Growth
+38.67% -105.06% -95.17% +6.87%
Net Margin Growth
-9.03% -15.35% -32.47% -30.05%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(2.71M) (5.55M) (10.83M) (10.09M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(2.71M) (5.55M) (10.83M) (10.09M)
EPS (Basic)
-0.7947 -1.5986 -3.1013 -2.6492
EPS (Basic) Growth
+39.46% -101.16% -94.00% +14.58%
Basic Shares Outstanding
3.41M 3.47M 3.49M 3.81M
EPS (Diluted)
-0.7947 -1.5986 -3.1013 -2.6492
EPS (Diluted) Growth
+39.46% -101.16% -94.00% +14.58%
Diluted Shares Outstanding
3.41M 3.47M 3.49M 3.81M
EBITDA
(316.00K) 1.04M (418.00K) (87.00K)
EBITDA Growth
-91.52% +428.80% -140.23% +79.19%
EBITDA Margin
-1.05% +2.87% -1.25% -0.26%

Snapshot

Average Recommendation BUY Average Target Price 7.40
Number of Ratings 2 Current Quarters Estimate -0.33
FY Report Date 12 / 2025 Current Year's Estimate -1.855
Last Quarter’s Earnings 0.004 Median PE on CY Estimate N/A
Year Ago Earnings 0.328 Next Fiscal Year Estimate -1.385
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.33 -0.42 -1.86 -1.39
High Estimates -0.26 -0.36 -1.80 -1.29
Low Estimate -0.40 -0.47 -1.91 -1.48
Coefficient of Variance -30.00 -18.74 -4.19 -9.70

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Strata Skin Sciences Inc in the News